Cytomegalovirus Disease
📧 Sign up to get email alerts when something new happens for Cytomegalovirus Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant Recipients [Phase 4]
Phase 4 clinical trial in Chinese kidney transplant recipients comparing Leymovir to valganciclovir for prevention of cytomegalovirus infect…
-
CLINICAL_TRIALS trial_result · 2025-07-29Clinical Trial Update: Letermovir Use in Heart Transplant Recipients [Phase 4]
Phase 4 clinical trial evaluating Letermovir use in heart transplant recipients has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2024-06-28Clinical Trial Update: A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection [Phase 2]
Phase 2 study in kidney transplant recipients at high risk of cytomegalovirus infection; results posted from a Nobelpharma-sponsored trial.
-
CLINICAL_TRIALS trial_result · 2024-04-01Clinical Trial Update: MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042) [Phase 3]
Phase 3 trial MK-8228-042 evaluated letermovir for CMV prophylaxis in adult Japanese kidney transplant recipients; results have been posted.
-
FDA approval · 2022-06-29FDA Approved: VALGANCICLOVIR HYDROCHLORIDE — Supplemental Application (Somerset Therapeutics, LLC)
The FDA approved a supplemental application to Somerset Therapeutics, LLC for valganciclovir hydrochloride (valganciclovir), authorizing a g…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-07-16Clinical Trial Update: A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus [Phase 3]
Phase 3 trial comparing brincidofovir to valganciclovir for prevention of cytomegalovirus in transplant patients; study terminated with post…
-
CLINICAL_TRIALS trial_result · 2021-07-16Clinical Trial Update: A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease [Phase 3]
Phase 3 trial comparing brincidofovir to valganciclovir for prevention of cytomegalovirus disease; study terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2020-12-16Clinical Trial Update: Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation [Phase 2]
Phase 2 trial investigating donor-derived CMVpp65 specific T-cells for treatment of CMV infection or persistent CMV viremia after allogeneic…
-
FDA approval · 2020-03-12FDA Approved: VALGANCICLOVIR — Supplemental Application (Strides Pharma Science Limited)
FDA approved a supplemental application for valganciclovir hydrochloride (generic product) from Strides Pharma Science Limited.
-
CLINICAL_TRIALS trial_result · 2018-10-04Clinical Trial Update: Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection [Phase 4]
Phase 4 clinical trial update on Cytogam administration in abdominal organ transplant recipients at high risk for cytomegalovirus infection;…
-
EMA approval · 2017-11-10New medicine to prevent cytomegalovirus disease in stem cell transplant patients
EMA announces a new medicine approved to prevent cytomegalovirus disease in stem cell transplant patients.
-
CLINICAL_TRIALS trial_result · 2015-06-26Clinical Trial Update: TT-CMV Observational Birth Cohort Study
A completed observational birth cohort study (TT-CMV) investigating cytomegalovirus disease.
-
CLINICAL_TRIALS trial_result · 2014-04-04Clinical Trial Update: Cut Off for the Diagnosis of Cytomegalovirus (CMV) Disease in Serum-positive Kidney Transplant Recipients
This clinical trial update reports a diagnostic cut-off for cytomegalovirus disease in serum-positive kidney transplant recipients. The tria…
-
FDA approval · 2013-03-28FDA Approved: VALCYTE — Supplemental Application (H2-Pharma, LLC)
The FDA approved a supplemental application for VALCYTE (valganciclovir) submitted by H2-Pharma, LLC.
-
CLINICAL_TRIALS trial_result · 2012-09-03Clinical Trial Update: Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients [Phase 2]
Phase 2 trial investigates Everolimus (Certican) for Cytomegalovirus disease in renal transplant patients. The trial status is currently unk…
-
CLINICAL_TRIALS trial_result · 2012-07-26Clinical Trial Update: The Impact of Cytogam® on Time to Viral Load Reduction in Kidney or Kidney/Pancreas Transplant Recipients With Clinical CMV Disease [NA]
This clinical trial evaluated whether Cytogam shortened the time to CMV viral load reduction in kidney and kidney/pancreas transplant recipi…